secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcutis Biotherapeutics, Inc. (ARQT)
CIK:        0001787306
Form:       8-K
Filed at:   2025-04-10T23:59:59+00:00
Accession:  0001787306-25-000058
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcutis appoints Latha Vairavan as CFO; David Topper to retire effective May 15, 2025
--------------------------------------------------------------------------------

- Latha Vairavan appointed SVP and CFO effective prior to Q1 10-Q filing; David Topper to retire with transition support through May 15, 2025.
- Vairavan's base salary increased to $450,000, target annual bonus 45% of salary (max 67.5%), pro-rated for 2025.
- Vairavan granted option to purchase 60,000 shares and 20,000 restricted stock units with standard vesting.
- Topper's retirement not due to any dispute; he will receive severance benefits per existing agreement subject to release.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787306/000178730625000058/0001787306-25-000058-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787306/000178730625000058/arqt-20250410.htm
  HTML page:      https://secwatch.observer/filing/0001787306-25-000058

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer